Market Access
Is Step Therapy Now a Possibility for Part B Drugs?
The Trump administration’s drug cost blueprint looked at the possibility of moving Part B ...
Seize the Day
The multiple forces dramatically reshaping the healthcare industry show no sign of abating. Influence ...
Breaking Opioid Addiction
Despite growing awareness of the dangers around opioid overuse, 30% of all people in ...
The Impact of Express Scripts’ 2019 Formulary Exclusion List
Earlier this month, Express Scripts announced its 2019 National Preferred Formulary (NPF), which added ...
Will Trump’s Blueprint for Lower Drug Prices Change the Price Negotiation Process?
Last month, the Trump administration once again made its desire to lower drug prices ...
Prescription Pushback
In value-based healthcare, health plans/PBMs, employers, and government-sponsored healthcare programs focus on optimizing patient ...
Creating Value in Bundled Payments
A debate has been brewing over the past few years surrounding the Center for ...
The Payer Landscape is Evolving—But Change is Slow
Payers are evolving. Just look at the recent deals that blend together some combination ...
Beyond Price Negotiation—What Really Matters to Payers
We’ve all heard the adage “cost is what you pay, value is what you ...
Achieving a Win-Win for Pharma and Payers in Contracting Agreements
The shift to value-based care and outcomes contracting type programs present the opportunity to ...
How Pharma Can Help Patients Feel Less Overwhelmed When Dealing with Payers
The integration of roles in the health system should theoretically result in better coordination ...
Using Artificial Intelligence to Expedite the Electronic Benefit Verification Process
Consumer technology continues to evolve at an incredible rate—from virtual reality experiences that drop ...
Four Key Questions About Payer/Provider Strategies
PM360 asked experts in engaging with payers and providers to address key issues the ...
